Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic

por Shah, Fenil, Logsdon, Derek, Messmann, Richard A., Fehrenbacher, Jill C., Fishel, Melissa L., Kelley, Mark R.
Publicado 2017

Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials

por Van Heertum, Ronald L, Scarimbolo, Robert, Wolodzko, John G, Klencke, Barbara, Messmann, Richard, Tunc, Feza, Sokol, Levi, Agarwal, Rajan, Strafaci, James A, O’Neal, Michael
Publicado 2017

A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors

por Tolcher, Anthony W., Rodrigueza, Wendi V., Rasco, Drew W., Patnaik, Amita, Papadopoulos, Kyriakos P., Amaya, Alex, Moore, Timothy D., Gaylor, Shari K., Bisgaier, Charles L., Sooch, Mina P., Woolliscroft, Michael J., Messmann, Richard A.
Publicado 2013

Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide

por Rodrigueza, Wendi V., Woolliscroft, Michael J., Ebrahim, Abdul-Shukkur, Forgey, Robert, McGovren, Patrick J., Endert, Gerold, Wagner, Andreas, Holewa, Danielle, Aboukameel, Amro, Gill, Richard D., Bisgaier, Charles L., Messmann, Richard A., Whitehead, Christopher E., Izbicka, Elzbieta, Streeper, Robert, Wick, Michael C., Stiegler, Gabriela, Stein, C. A., Monsma, David, Webb, Craig, Sooch, Mina P., Panzner, Steffen, Mohammad, Ramzi, Goodwin, Neal C., Al-Katib, Ayad
Publicado 2014